JP2010539244A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010539244A5 JP2010539244A5 JP2010525985A JP2010525985A JP2010539244A5 JP 2010539244 A5 JP2010539244 A5 JP 2010539244A5 JP 2010525985 A JP2010525985 A JP 2010525985A JP 2010525985 A JP2010525985 A JP 2010525985A JP 2010539244 A5 JP2010539244 A5 JP 2010539244A5
- Authority
- JP
- Japan
- Prior art keywords
- pain
- compound
- compound according
- acute
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 150000001875 compounds Chemical class 0.000 claims description 70
- 208000002193 Pain Diseases 0.000 claims description 66
- 230000001154 acute effect Effects 0.000 claims description 20
- 125000001424 substituent group Chemical group 0.000 claims description 17
- 208000004296 neuralgia Diseases 0.000 claims description 14
- 230000001684 chronic effect Effects 0.000 claims description 13
- 239000000203 mixture Substances 0.000 claims description 13
- 208000008035 Back Pain Diseases 0.000 claims description 12
- 208000008930 Low Back Pain Diseases 0.000 claims description 12
- 125000001118 alkylidene group Chemical group 0.000 claims description 10
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims description 10
- 208000005298 acute pain Diseases 0.000 claims description 8
- 208000021722 neuropathic pain Diseases 0.000 claims description 8
- 229910052757 nitrogen Inorganic materials 0.000 claims description 8
- 229910052760 oxygen Inorganic materials 0.000 claims description 8
- 229910052717 sulfur Inorganic materials 0.000 claims description 8
- 206010019233 Headaches Diseases 0.000 claims description 7
- 208000004404 Intractable Pain Diseases 0.000 claims description 7
- 208000019695 Migraine disease Diseases 0.000 claims description 7
- 208000004550 Postoperative Pain Diseases 0.000 claims description 7
- 206010027599 migraine Diseases 0.000 claims description 7
- 201000006417 multiple sclerosis Diseases 0.000 claims description 7
- 230000002981 neuropathic effect Effects 0.000 claims description 7
- 201000001119 neuropathy Diseases 0.000 claims description 7
- 230000007823 neuropathy Effects 0.000 claims description 7
- 208000033808 peripheral neuropathy Diseases 0.000 claims description 7
- 208000009935 visceral pain Diseases 0.000 claims description 7
- 208000005615 Interstitial Cystitis Diseases 0.000 claims description 6
- 125000005842 heteroatom Chemical group 0.000 claims description 6
- 229920006395 saturated elastomer Polymers 0.000 claims description 6
- 208000000003 Breakthrough pain Diseases 0.000 claims description 5
- 206010058019 Cancer Pain Diseases 0.000 claims description 5
- 208000006561 Cluster Headache Diseases 0.000 claims description 5
- 208000023890 Complex Regional Pain Syndromes Diseases 0.000 claims description 5
- 208000007514 Herpes zoster Diseases 0.000 claims description 5
- 206010065390 Inflammatory pain Diseases 0.000 claims description 5
- 206010028836 Neck pain Diseases 0.000 claims description 5
- 206010036376 Postherpetic Neuralgia Diseases 0.000 claims description 5
- 206010059604 Radicular pain Diseases 0.000 claims description 5
- 208000008765 Sciatica Diseases 0.000 claims description 5
- 208000018912 cluster headache syndrome Diseases 0.000 claims description 5
- 208000014674 injury Diseases 0.000 claims description 5
- 208000002551 irritable bowel syndrome Diseases 0.000 claims description 5
- 206010044652 trigeminal neuralgia Diseases 0.000 claims description 5
- 206010002383 Angina Pectoris Diseases 0.000 claims description 4
- 208000006820 Arthralgia Diseases 0.000 claims description 4
- 208000000094 Chronic Pain Diseases 0.000 claims description 4
- 208000006011 Stroke Diseases 0.000 claims description 4
- 230000002159 abnormal effect Effects 0.000 claims description 4
- 125000002619 bicyclic group Chemical group 0.000 claims description 4
- 125000005843 halogen group Chemical group 0.000 claims description 4
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 4
- 201000008482 osteoarthritis Diseases 0.000 claims description 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 4
- 230000008733 trauma Effects 0.000 claims description 4
- 208000019901 Anxiety disease Diseases 0.000 claims description 3
- 206010003591 Ataxia Diseases 0.000 claims description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 3
- 208000032131 Diabetic Neuropathies Diseases 0.000 claims description 3
- 206010021639 Incontinence Diseases 0.000 claims description 3
- 208000016285 Movement disease Diseases 0.000 claims description 3
- 206010061533 Myotonia Diseases 0.000 claims description 3
- 208000001294 Nociceptive Pain Diseases 0.000 claims description 3
- 230000036506 anxiety Effects 0.000 claims description 3
- 206010003119 arrhythmia Diseases 0.000 claims description 3
- 230000006793 arrhythmia Effects 0.000 claims description 3
- 206010003246 arthritis Diseases 0.000 claims description 3
- 206010015037 epilepsy Diseases 0.000 claims description 3
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 3
- 208000015706 neuroendocrine disease Diseases 0.000 claims description 3
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 3
- 208000020016 psychiatric disease Diseases 0.000 claims description 3
- 230000001568 sexual effect Effects 0.000 claims description 3
- 208000011580 syndromic disease Diseases 0.000 claims description 3
- 230000009885 systemic effect Effects 0.000 claims description 3
- 208000004998 Abdominal Pain Diseases 0.000 claims description 2
- 206010000087 Abdominal pain upper Diseases 0.000 claims description 2
- 206010003011 Appendicitis Diseases 0.000 claims description 2
- 208000009137 Behcet syndrome Diseases 0.000 claims description 2
- 208000020925 Bipolar disease Diseases 0.000 claims description 2
- 206010006002 Bone pain Diseases 0.000 claims description 2
- 201000006474 Brain Ischemia Diseases 0.000 claims description 2
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 claims description 2
- 125000000041 C6-C10 aryl group Chemical group 0.000 claims description 2
- 206010064012 Central pain syndrome Diseases 0.000 claims description 2
- 206010008120 Cerebral ischaemia Diseases 0.000 claims description 2
- 206010008479 Chest Pain Diseases 0.000 claims description 2
- 206010011796 Cystitis interstitial Diseases 0.000 claims description 2
- 201000009273 Endometriosis Diseases 0.000 claims description 2
- 206010015150 Erythema Diseases 0.000 claims description 2
- 208000024720 Fabry Disease Diseases 0.000 claims description 2
- 206010019909 Hernia Diseases 0.000 claims description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 2
- 206010020772 Hypertension Diseases 0.000 claims description 2
- 206010020853 Hypertonic bladder Diseases 0.000 claims description 2
- 206010024229 Leprosy Diseases 0.000 claims description 2
- 206010026749 Mania Diseases 0.000 claims description 2
- 206010028391 Musculoskeletal Pain Diseases 0.000 claims description 2
- 208000030858 Myofascial Pain Syndromes Diseases 0.000 claims description 2
- 208000005890 Neuroma Diseases 0.000 claims description 2
- 208000009722 Overactive Urinary Bladder Diseases 0.000 claims description 2
- 206010033557 Palpitations Diseases 0.000 claims description 2
- 206010033645 Pancreatitis Diseases 0.000 claims description 2
- 206010033647 Pancreatitis acute Diseases 0.000 claims description 2
- 208000010886 Peripheral nerve injury Diseases 0.000 claims description 2
- 208000004983 Phantom Limb Diseases 0.000 claims description 2
- 206010056238 Phantom pain Diseases 0.000 claims description 2
- 206010037596 Pyelonephritis Diseases 0.000 claims description 2
- 206010037779 Radiculopathy Diseases 0.000 claims description 2
- 206010040037 Sensory neuropathy hereditary Diseases 0.000 claims description 2
- 206010043269 Tension headache Diseases 0.000 claims description 2
- 208000008548 Tension-Type Headache Diseases 0.000 claims description 2
- 208000009205 Tinnitus Diseases 0.000 claims description 2
- 206010046543 Urinary incontinence Diseases 0.000 claims description 2
- 208000025609 Urogenital disease Diseases 0.000 claims description 2
- 201000003229 acute pancreatitis Diseases 0.000 claims description 2
- 239000002671 adjuvant Substances 0.000 claims description 2
- 125000000217 alkyl group Chemical group 0.000 claims description 2
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 2
- 208000034757 axonal type 2FF Charcot-Marie-Tooth disease Diseases 0.000 claims description 2
- 208000029028 brain injury Diseases 0.000 claims description 2
- 206010008118 cerebral infarction Diseases 0.000 claims description 2
- 238000002512 chemotherapy Methods 0.000 claims description 2
- 201000001352 cholecystitis Diseases 0.000 claims description 2
- 206010012601 diabetes mellitus Diseases 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 231100000321 erythema Toxicity 0.000 claims description 2
- 230000002496 gastric effect Effects 0.000 claims description 2
- 231100000869 headache Toxicity 0.000 claims description 2
- 208000037584 hereditary sensory and autonomic neuropathy Diseases 0.000 claims description 2
- 201000006847 hereditary sensory neuropathy Diseases 0.000 claims description 2
- 125000001072 heteroaryl group Chemical group 0.000 claims description 2
- 125000000623 heterocyclic group Chemical group 0.000 claims description 2
- 229910052739 hydrogen Inorganic materials 0.000 claims description 2
- 239000001257 hydrogen Substances 0.000 claims description 2
- 230000006698 induction Effects 0.000 claims description 2
- 230000002757 inflammatory effect Effects 0.000 claims description 2
- 208000003243 intestinal obstruction Diseases 0.000 claims description 2
- 125000002950 monocyclic group Chemical group 0.000 claims description 2
- 208000020629 overactive bladder Diseases 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 208000001297 phlebitis Diseases 0.000 claims description 2
- 201000007094 prostatitis Diseases 0.000 claims description 2
- 238000001959 radiotherapy Methods 0.000 claims description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims description 2
- 208000007056 sickle cell anemia Diseases 0.000 claims description 2
- 208000020431 spinal cord injury Diseases 0.000 claims description 2
- 208000005198 spinal stenosis Diseases 0.000 claims description 2
- 230000007863 steatosis Effects 0.000 claims description 2
- 231100000240 steatosis hepatitis Toxicity 0.000 claims description 2
- 210000001738 temporomandibular joint Anatomy 0.000 claims description 2
- 125000001113 thiadiazolyl group Chemical group 0.000 claims description 2
- 125000000437 thiazol-2-yl group Chemical group [H]C1=C([H])N=C(*)S1 0.000 claims description 2
- 125000000335 thiazolyl group Chemical group 0.000 claims description 2
- 231100000886 tinnitus Toxicity 0.000 claims description 2
- 208000004371 toothache Diseases 0.000 claims description 2
- 239000003981 vehicle Substances 0.000 claims description 2
- 208000001640 Fibromyalgia Diseases 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 208000027418 Wounds and injury Diseases 0.000 claims 1
- 150000001728 carbonyl compounds Chemical class 0.000 claims 1
- 230000006378 damage Effects 0.000 claims 1
- 210000003414 extremity Anatomy 0.000 claims 1
- 230000001771 impaired effect Effects 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 230000003211 malignant effect Effects 0.000 claims 1
- 210000005036 nerve Anatomy 0.000 claims 1
- 210000000689 upper leg Anatomy 0.000 claims 1
- 208000026533 urinary bladder disease Diseases 0.000 claims 1
- 0 C*N(C1CC=CCCCC(C)C1)S(C)(=O)=O Chemical compound C*N(C1CC=CCCCC(C)C1)S(C)(=O)=O 0.000 description 17
- 238000000034 method Methods 0.000 description 7
- JUJWROOIHBZHMG-UHFFFAOYSA-N c1ccncc1 Chemical compound c1ccncc1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 3
- LPAGFVYQRIESJQ-UHFFFAOYSA-N C1c2ccccc2NC1 Chemical compound C1c2ccccc2NC1 LPAGFVYQRIESJQ-UHFFFAOYSA-N 0.000 description 2
- XMSNMAGPGAYJHP-UHFFFAOYSA-N CSCC1c2ccccc2NCC1 Chemical compound CSCC1c2ccccc2NCC1 XMSNMAGPGAYJHP-UHFFFAOYSA-N 0.000 description 2
- 208000007914 Labor Pain Diseases 0.000 description 2
- 208000035945 Labour pain Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 206010016059 Facial pain Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000000450 Pelvic Pain Diseases 0.000 description 1
- 206010038419 Renal colic Diseases 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 208000014617 hemorrhoid Diseases 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 201000009890 sinusitis Diseases 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US99442307P | 2007-09-19 | 2007-09-19 | |
| PCT/US2008/076928 WO2009039328A1 (en) | 2007-09-19 | 2008-09-19 | Pyridyl sulfonamides as modulators of ion channels |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010539244A JP2010539244A (ja) | 2010-12-16 |
| JP2010539244A5 true JP2010539244A5 (enExample) | 2012-11-29 |
Family
ID=40352214
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010525985A Withdrawn JP2010539244A (ja) | 2007-09-19 | 2008-09-19 | イオンチャネルのモジュレーターとしてのピリジルスルホンアミド |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US7994174B2 (enExample) |
| EP (1) | EP2201008A1 (enExample) |
| JP (1) | JP2010539244A (enExample) |
| CN (1) | CN101842372A (enExample) |
| AU (1) | AU2008302205A1 (enExample) |
| CA (1) | CA2699892A1 (enExample) |
| MX (1) | MX2010003009A (enExample) |
| NZ (1) | NZ584009A (enExample) |
| WO (1) | WO2009039328A1 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7615563B2 (en) * | 2003-08-08 | 2009-11-10 | Gonzalez Iii Jesus E | Compositions useful as inhibitors of voltage-gated sodium channels |
| MX2007014180A (es) | 2005-05-10 | 2008-01-14 | Vertex Pharma | Derivados biciclicos como moduladores de canales de iones. |
| ZA200710332B (en) * | 2005-05-16 | 2009-03-25 | Vertex Pharma | Bicyclic derivatives as modulators of ion channels |
| AU2006287480B2 (en) * | 2005-09-09 | 2012-07-05 | Vertex Pharmaceuticals Incorporated | Bicyclic derivatives as modulators of voltage gated ion channels |
| CN101331115A (zh) * | 2005-10-21 | 2008-12-24 | 沃泰克斯药物股份有限公司 | 调控离子通道的衍生物 |
| JP2009524591A (ja) * | 2005-12-21 | 2009-07-02 | バーテックス ファーマシューティカルズ インコーポレイテッド | イオンチャネルのモジュレーターとしての複素環誘導体 |
| TWI362930B (en) | 2007-04-27 | 2012-05-01 | Purdue Pharma Lp | Trpv1 antagonists and uses thereof |
| AU2008256937A1 (en) | 2007-05-25 | 2008-12-04 | Vertex Pharmaceuticals Incorporated | Ion channel modulators and methods of use |
| ATE540036T1 (de) * | 2007-11-13 | 2012-01-15 | Vertex Pharma | Heterocyclische derivate als ionenkanalmodulatoren |
| CA2705336A1 (en) | 2007-11-13 | 2009-05-22 | Vertex Pharmaceuticals Incorporated | Heterocyclic derivatives as modulators of ion channels |
| CN102099356A (zh) * | 2008-07-01 | 2011-06-15 | 沃泰克斯药物股份有限公司 | 用作离子通道调节剂的杂环衍生物 |
| CN102574789B (zh) * | 2009-09-21 | 2014-12-10 | 凯莫森特里克斯股份有限公司 | 吡咯烷酮甲酰胺衍生物作为趋化素-r(chemr23)调节剂 |
| SI2723732T1 (sl) | 2011-06-22 | 2017-05-31 | Purdue Pharma Lp One Stamford Forum | Antagonisti trpv1, vključno z dihidroksi substituentom, in njihova uporaba |
| HUE030031T2 (en) | 2011-06-27 | 2017-04-28 | Newron Pharm Spa | Fluorinated arylalkylaminocarboxamide derivatives |
| US10510973B2 (en) * | 2014-12-17 | 2019-12-17 | Universal Display Corporation | Color-stable organic light emitting diode stack |
| US11034669B2 (en) | 2018-11-30 | 2021-06-15 | Nuvation Bio Inc. | Pyrrole and pyrazole compounds and methods of use thereof |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7615356B2 (en) | 2000-07-10 | 2009-11-10 | Vertex Pharmaceuticals (San Diego) Llc | Ion channel assay methods |
| WO2004103980A1 (en) | 2003-05-21 | 2004-12-02 | Biovitrum Ab | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type i |
| US7615563B2 (en) * | 2003-08-08 | 2009-11-10 | Gonzalez Iii Jesus E | Compositions useful as inhibitors of voltage-gated sodium channels |
| KR20060073930A (ko) * | 2003-08-08 | 2006-06-29 | 버텍스 파마슈티칼스 인코포레이티드 | 통증 치료시 나트륨 또는 칼슘 채널 차단제로서 유용한헤테로아릴아미노설포닐페닐 유도체 |
| JP2007261945A (ja) | 2004-04-07 | 2007-10-11 | Taisho Pharmaceut Co Ltd | チアゾール誘導体 |
| MX2007014180A (es) * | 2005-05-10 | 2008-01-14 | Vertex Pharma | Derivados biciclicos como moduladores de canales de iones. |
| ZA200710332B (en) * | 2005-05-16 | 2009-03-25 | Vertex Pharma | Bicyclic derivatives as modulators of ion channels |
| GT200600196A (es) * | 2005-05-23 | 2007-01-15 | Compuestos n-formil de hidroxilamina | |
| ZA200800191B (en) * | 2005-06-09 | 2009-04-29 | Vertex Pharmaceuicals Inc | Indane derivatives as modulators of ion channels |
| AU2006287480B2 (en) * | 2005-09-09 | 2012-07-05 | Vertex Pharmaceuticals Incorporated | Bicyclic derivatives as modulators of voltage gated ion channels |
| EP1934191B1 (en) * | 2005-10-12 | 2012-03-28 | Vertex Pharmaceuticals, Inc. | Biphenyl derivatives as modulators of voltage gated ion channels |
| CN101331115A (zh) * | 2005-10-21 | 2008-12-24 | 沃泰克斯药物股份有限公司 | 调控离子通道的衍生物 |
| JP2009524591A (ja) * | 2005-12-21 | 2009-07-02 | バーテックス ファーマシューティカルズ インコーポレイテッド | イオンチャネルのモジュレーターとしての複素環誘導体 |
| ATE540036T1 (de) * | 2007-11-13 | 2012-01-15 | Vertex Pharma | Heterocyclische derivate als ionenkanalmodulatoren |
| CA2705336A1 (en) * | 2007-11-13 | 2009-05-22 | Vertex Pharmaceuticals Incorporated | Heterocyclic derivatives as modulators of ion channels |
| CN102099356A (zh) * | 2008-07-01 | 2011-06-15 | 沃泰克斯药物股份有限公司 | 用作离子通道调节剂的杂环衍生物 |
-
2008
- 2008-09-17 US US12/212,063 patent/US7994174B2/en not_active Expired - Fee Related
- 2008-09-19 CA CA2699892A patent/CA2699892A1/en not_active Abandoned
- 2008-09-19 WO PCT/US2008/076928 patent/WO2009039328A1/en not_active Ceased
- 2008-09-19 NZ NZ584009A patent/NZ584009A/en not_active IP Right Cessation
- 2008-09-19 CN CN200880113677A patent/CN101842372A/zh active Pending
- 2008-09-19 MX MX2010003009A patent/MX2010003009A/es active IP Right Grant
- 2008-09-19 JP JP2010525985A patent/JP2010539244A/ja not_active Withdrawn
- 2008-09-19 AU AU2008302205A patent/AU2008302205A1/en not_active Abandoned
- 2008-09-19 EP EP08831349A patent/EP2201008A1/en not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010539244A5 (enExample) | ||
| JP2011526919A5 (enExample) | ||
| JP2011503112A5 (enExample) | ||
| JP2014508756A5 (enExample) | ||
| JP2010528035A5 (enExample) | ||
| RU2010123781A (ru) | Производные 4-(2-фенил)-морфолино)-2-оксопирролидин-1-ил)-n-(тиазол-2-ил)бензолсульфонамида и родственные соединения в качестве модуляторов ионных каналов для лечения боли | |
| ES2981592T3 (es) | Derivados de 6-(4-amino-3-metil-2-oxa-8-azaespiro[4.5]decan-8-il)-3-(2,3-diclorofenil)-2-metilpirimidin-4(3H)-ona y compuestos relacionados como inhibidores de PTPN11 (SHP2) para tratar el cáncer | |
| JP2011500598A5 (enExample) | ||
| RU2009100159A (ru) | Тиенопирамидины, полезные в качестве модуляторов ионных каналов | |
| JP2011503191A5 (enExample) | ||
| JP2014504642A5 (enExample) | ||
| RU2010123876A (ru) | Гетероциклические производные в качестве модуляторов ионных каналов | |
| JP2014508169A5 (enExample) | ||
| US9309224B2 (en) | N-acyl-N′-(pyridin-2-yl) ureas and analogs exhibiting anti-cancer and anti-proliferative activities | |
| RU2016104080A (ru) | Амиды конденсированного пиперидина в качестве модуляторов ионных каналов | |
| JP2009544618A5 (enExample) | ||
| MXPA04009784A (es) | Tiazolidin-4-carbonitrilos y analogos y su uso como inhibidores de dipeptidil-peptidas. | |
| RU2007111897A (ru) | Хиназолины, полезные в качестве модуляторов ионных каналов перекрестные ссылки на родственные заявки | |
| WO2021195475A1 (en) | Process, compositions, and crystalline forms of substituted pyridinone-pyridinyl compounds | |
| JP7331843B2 (ja) | Ｂｔｋ阻害活性を有する化合物を有効成分として含む自己免疫疾患の予防および／または治療剤 | |
| EA034759B1 (ru) | Пролекарства рилузола и их применение | |
| RU2006101452A (ru) | Пиридазинил-пиперазины и их применение в качестве лигандов h3 гистаминового рецептора | |
| JP2011500599A5 (enExample) | ||
| JP2008511670A5 (enExample) | ||
| EA025086B9 (ru) | Производные индоламида и родственные соединения для использования при лечении нейродегенеративных заболеваний |